Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

To observe the 1-year disease-free survival rate （1-year PFS） of patients with resectable esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy combined with camrelizumab and achieved clinical complete remission with watchful waiting strategy.

Trial Details

NCT ID

NCT05507411

Phase

PHASE2

Sponsor

Zhejiang Cancer Hospital

Status

RECRUITING

Cancer Type

Esophageal Cancer

Interventions

Neoadjuvant Radiotherapy
Neoadjuvant Chemotherapy
Immunotherapy

Locations (sample)

Hanzhou, Zhejiang, China
Hanzhou, Zhejiang, China
Ningbo, Zhejiang, China|29.87819,121.54945

Key Eligibility Criteria

Sign the informed consent. Participants signed and dated written informed consent. Informed consent must be signed prior to any protocol-related pr…
Participant type and target disease characteristics Eastern Collaboration Group (ECOG) physical status score 0-1； Histologically confirmed esophage…
Age and reproductive status Age ≥18 years old and ≤75 years old； Females of childbearing potential (WOCBP) must have a negative serum or urine preg…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →